Ausgabe 2/2023
Inhalt (20 Artikel)
CAR γδ T cells for cancer immunotherapy. Is the field more yellow than green?
Thamizhselvi Ganapathy, Rajalingam Radhakrishnan, Seth Sakshi, Sunil Martin
Preclinical development of a vaccine-based immunotherapy regimen (VBIR) that induces potent and durable T cell responses to tumor-associated self-antigens
Helen Cho, Joe Binder, Risini Weeratna, Michael Dermyer, Stanley Dai, Antionio Boccia, Wei Li, Shangjin Li, Karin Jooss, James Merson, Robert E. Hollingsworth
Personalized tumor vaccine for pancreatic cancer
Shira Orr, Ling Huang, James Moser, Dina Stroopinsky, Omar Gandarilla, Cori DeCicco, Jessica Liegel, Cansu Tacettin, Adam Ephraim, Giulia Cheloni, Daniela Torres, Donald Kufe, Jacalyn Rosenblatt, Manuel Hidalgo, Senthil K. Muthuswamy, David Avigan
High abundance of Lachnospiraceae in the human gut microbiome is related to high immunoscores in advanced colorectal cancer
Zhang Hexun, Toru Miyake, Takeru Maekawa, Haruki Mori, Daiki Yasukawa, Masashi Ohno, Atsushi Nishida, Akira Andoh, Masaji Tani
Interleukin-32γ promotes macrophage-mediated chemoresistance by inducing CSF1-dependent M2 macrophage polarization in multiple myeloma
Haimeng Yan, Donghua He, Jianwei Qu, Yang Liu, Ruyi Xu, Huiyao Gu, Jing Chen, Yi Li, Enfan Zhang, Yi Zhao, Jingsong He, Zhen Cai
Comparison of the tumor immune microenvironment and checkpoint blockade biomarkers between stage III and IV non-small cell lung cancer
Yinjie Gao, Michelle M. Stein, Matthew Kase, Amy L. Cummings, Ramit Bharanikumar, Denise Lau, Edward B. Garon, Sandip P. Patel
A Fc-VEGF chimeric fusion enhances PD-L1 immunotherapy via inducing immune reprogramming and infiltration in the immunosuppressive tumor microenvironment
Cheng-Liang Kuo, Han-Yu Chou, Hui-Wen Lien, Chia-An Yeh, Jing-Rong Wang, Chung-Hsing Chen, Chi-Chen Fan, Chih-Ping Hsu, Ting-Yu Kao, Tai-Ming Ko, Alan Yueh-Luen Lee
Dynamic changes in peripheral blood monocytes early after anti-PD-1 therapy predict clinical outcomes in hepatocellular carcinoma
Seung Hyuck Jeon, Yong Joon Lee, Hyung-Don Kim, Heejin Nam, Baek-Yeol Ryoo, Su-Hyung Park, Changhoon Yoo, Eui-Cheol Shin
Association of hepatitis B virus DNA levels with overall survival for advanced hepatitis B virus-related hepatocellular carcinoma under immune checkpoint inhibitor therapy
Mengchao An, Wenkang Wang, Jie Zhang, Brian G. Till, Lingdi Zhao, Hao Huang, Yonghao Yang, Tiepeng Li, Lu Han, Xiaojie Zhang, Peng Qin, Yunjian Wang, Min Zhang, Hong Cui, Quanli Gao, Zibing Wang
Single-cell analysis of peripheral CD8+ T cell responses in patients receiving checkpoint blockade immunotherapy for cancer
Niloufar Khojandi, Louis Connelly, Alexander Piening, Stella G. Hoft, Michelle Pherson, Maureen J. Donlin, Richard J. DiPaolo, Ryan M. Teague
Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer
Jiannan Chen, Jianhua Hu, Lili Gu, Feng Ji, Fan Zhang, Miaomiao Zhang, Jun Li, Zhengliang Chen, Longwei Jiang, Yan Zhang, Ruifang Shi, Lihua Ma, Shaochang Jia, Ying Zhang, Qi Zhang, Junqing Liang, Shunyu Yao, Zhigang Hu, Zhigang Guo
Inflammatory prognostic factors in advanced or recurrent esophageal squamous cell carcinoma treated with nivolumab
Tatsuki Ikoma, Mototsugu Shimokawa, Toshihiko Matsumoto, Shogen Boku, Tomoyo Yasuda, Nobuhiro Shibata, Yusuke Kurioka, Masahiro Takatani, Tetsuji Nobuhisa, Tsutomu Namikawa, Hiroyuki Kitagawa, Kazuhiro Hanazaki, Keitaro Doi, Takanobu Shimada, Takehiko Tsumura, Hiroyuki Marusawa, Seichiro Kanaya, Shuko Morita, Tetsurou Inokuma, Hiroki Nagai, Hisateru Yasui, Hironaga Satake
Low-dose anlotinib confers improved survival in combination with immune checkpoint inhibitor in advanced non-small cell lung cancer patients
Shumin Yuan, Ling Peng, Yuqing Liu, Brian G. Till, Xiang Yan, Jie Zhang, Liping Zhu, Huijuan Wang, Shaokai Zhang, Hongle Li, Quanli Gao, Zibing Wang
Immune checkpoint inhibitors combined with angiogenic inhibitors in the treatment of locally advanced or metastatic lung adenocarcinoma patients
Yu Feng, Le Tang, Hongyu Wang, Yutao Liu, Sheng Yang, Lin Lin, Xingsheng Hu, Yuankai Shi
Soluble CD163: a novel independent prognostic biomarker in patients with metastatic renal cell carcinoma
Kasper Munch Lauridsen, Marianne Hokland, Sinan Al-Karradi, Holger Jon Møller, Frede Donskov, Morten Nørgaard Andersen
Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results of the phase II PRIMMO study
Emiel A. De Jaeghere, Sandra Tuyaerts, An M. T. Van Nuffel, Ann Belmans, Kris Bogaerts, Regina Baiden-Amissah, Lien Lippens, Peter Vuylsteke, Stéphanie Henry, Xuan Bich Trinh, Peter A. van Dam, Sandrine Aspeslagh, Alex De Caluwé, Eline Naert, Diether Lambrechts, An Hendrix, Olivier De Wever, Koen K. Van de Vijver, Frédéric Amant, Katrien Vandecasteele, Hannelore G. Denys
Characterization of anti-CD79b/CD3 bispecific antibody, a potential therapy for B cell malignancies
Jie Wang, Chen Li, Kaijie He, Zhihui Kuang, Jia Lu, Ying Yao, Fufan He, Ninghuan Li, Li Li, Fenggen Fu, Zhihai Wu, Shuaixiang Zhou, Dian Kang, Xuan Qiu, Min Wu, Yang Liu, Xiaochao Cao, Mengqiu Xu, Bingliang Chen, Weiwei Wu, Feng Guo
Cytokine alterations during paraneoplastic neutrophilia and leukemoid reaction in patients with advanced melanoma
Xin-Wen Zhang, Alexander Wald, Martin Salzmann, Niels Halama, Jessica C. Hassel
Immune phenotypes and checkpoint molecule expression of clonally expanded lymph node-infiltrating T cells in classical Hodgkin lymphoma
Alexej Ballhausen, Amin Ben Hamza, Carlotta Welters, Kerstin Dietze, Lars Bullinger, Hans-Peter Rahn, Sylvia Hartmann, Martin-Leo Hansmann, Leo Hansmann
Bloody pericardial effusion during chemotherapy with immune checkpoint inhibitors
Yuika Sasatani, Eiji Ojima, Hiroaki Satoh